Other leukocyte surface antigens on B cells, NK cells, and myeloid cells

The term "Other leukocyte surface antigens on B cells, NK cells, and myeloid cells" refers to a broad classification used in clinical and pharmacological contexts to group various cell surface proteins that are not categorized under primary headings like CD19 or CD20. This group encompasses a diverse array of Cluster of Differentiation (CD) markers and other membrane-bound proteins that are essential for the development, activation, and effector functions of B lymphocytes, natural killer (NK) cells, and myeloid cells such as monocytes and granulocytes (Source: Murphy K, Weaver C. Janeway's Immunobiology. 9th ed. Garland Science; 2016). These antigens often serve as receptors for cytokines, adhesion molecules for extravasation, or signaling hubs for immune activation (Source: National Cancer Institute Thesaurus, "Leukocyte Antigen"). In drug development, specific antigens within this category—such as CD22, CD33, CD38, and CD123—are targeted by monoclonal antibodies and antibody-drug conjugates to treat hematologic malignancies like acute myeloid leukemia and multiple myeloma (Source: WHO International Clinical Trials Registry Platform). Because this is a collective term for multiple distinct molecules rather than a single receptor or enzyme, the therapeutic profile, including efficacy and safety, depends entirely on the specific antigen being targeted.

Other names

Leukocyte surface antigensCluster of differentiation antigensNon-CD19/CD20 leukocyte markersImmune cell surface markers

Varies by specific target; mechanisms include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and targeted delivery of cytotoxic payloads (Source: PubMed, PMID: 30232619).